The Food and Drug Administration (FDA) extended the indication of gemtuzumab ozogamicin for newly-diagnosed CD33-positive acute myeloid leukaemia (AML) to include paediatric patients 1 month and older.
Efficacy and safety in the paediatric population were supported by data from AAML0531 (NCT00372593), a multi-centre randomised study of 1,063 patients with newly-diagnosed AML ages 0 to 29 years.
Patients were randomised to 5-cycle chemotherapy alone or with gemtuzumab ozogamicin (3 mg/m2) administered once on day 6 in Induction 1 and once on day 7 in Intensification 2.
The main efficacy outcome measure was event-free survival (EFS) measured from the date of trial entry until induction failure, relapse, or death by any cause.
The EFS hazard ratio was 0.84 (95% CI: 0.71-0.99).
The estimated percentage of patients free of induction failure, relapse, or death at five years was 48% (95% CI: 43%-52%) in the gemtuzumab ozogamicin chemotherapy arm versus 40% (95% CI: 36%‑45%) in the chemotherapy alone arm.
No difference between treatment arms in overall survival was demonstrated.
The most common grade 3 and higher adverse reactions that occurred during Induction 1 and Intensification 2 in ≥ 5% of patients who received gemtuzumab ozogamicin were infection, febrile neutropenia, decreased appetite, hyperglycaemia, mucositis, hypoxia, haemorrhage, increased transaminase, diarrhoea, nausea, and hypotension.
Source: The Food and Drug Administration
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.